Search
Filter Results
Displaying 21–30 of 802 for “retinitis clinical trial”
-
May 2, 2023
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Known as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
Aug 18, 2016
Optogenetic Therapy Takes First Step Forward in Clinical Trial
RetroSense’s optogenetic therapy is designed to restore vision to people who are completely blind from retinal degenerative diseases such as retinitis pigmentosa by bestowing light sensitivity to retinal ganglion cells, which survive after photoreceptors, the cells that make vision possible, are lost.
-
Apr 16, 2019
First Patient Receives AON Therapy for LCA10 in ProQR’s Phase 2/3 Clinical Trial
The treatment, formerly known as QR-110, is designed for people with the retinal disease Leber congenital amaurosis 10
-
Jan 17, 2018
Clinical Trial to Launch for System Combining Optogenetics and Eyewear
The French biotech GenSight Biologics has received regulatory authorization in the UK to launch the PIONEER Phase 1 \ 2 clinical trial for its GS030 system — a light-sensing gene therapy (optogenetics) coupled with eyewear, which enhances visual stimulation.
-
May 17, 2022
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
The three-month results support the planned launch of the company’s Phase 2/3 Vista trial
-
Jun 1, 2017
Valproic Acid's Effect Too Small in One-Year Clinical Trial
While a therapy for adRP will not emerge from the clinical trial, study investigators advanced development of a new outcome measure known as EZ Area to quickly and accurately evaluate potential therapies for RP in human studies.
-
Feb 21, 2019
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
ReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
-
Mar 24, 2021
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
The company is planning two Phase 2/3 clinical trials for the treatment
-
Sep 18, 2023
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
The company is also launching modifier gene therapy clinical trials for GA and Stargardt disease